Alzheimer’s Disease – Geographic Focus: China – DIA: Alzheimer’s Disease | China In-Depth | China | 2026

Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disorder characterized by cognitive decline, memory impairment, and loss of functional independence. In China, current management remains heavily reliant on long-standing symptomatic therapies that offer limited clinical improvement, highlighting significant unmet need and opportunity for disease-modifying therapies. The launches of Eisai / Biogen’s lecanemab (Leqembi) in 2024—followed by approval of its IV maintenance regimen in 2025 and ongoing review of its SC formulation—and Eli Lilly’s Kisunla (donanemab) in 2024 have introduced a new competitive dynamic in this market. With additional disease-modifying therapies expected to enter the market, China’s AD landscape is on the verge of substantial expansion over the forecast period. This report provides an in-depth assessment of China’s AD market landscape, including current treatment patterns, unmet needs, and the commercial outlook for current and emerging therapies, and evaluates how evolving pricing, coverage, and regulatory reforms may shape the uptake dynamics.

Questions answered

• How large is China’s drug-treatable AD population, and how will drug-treatment rates change during the forecast period?
• What are interviewed experts’ insights into current treatment options?
• What are the key unmet needs in the management of AD in China?
• What are the key market access considerations for therapies in the AD pipeline in China? What sales/uptake could they secure in AD?
• What are the key drivers of and constraints in China’s AD therapy market, and how will the market evolve over the forecast period?

Product description

China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy in China.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.

Primary research: Qualitative and quantitative insights driven from 5 thought-leader interviews and surveys with 50 neurologists

Epidemiology: Diagnosed prevalence of AD patients in urban versus rural China; clinically and commercially relevant drug-treatable populations

Forecast: 10-year, annualized, drug-level sales and patient share of key therapies through 2035, based on primary and secondary market research to formulate bottom-up assumptions

Drug treatments: Coverage of key current and late-phase emerging therapies

Custom drug modeler: Integrated tool to input customized forecast assumptions (e.g., launch date, price)